Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 2
2008 4
2009 2
2010 3
2011 2
2012 3
2013 1
2014 2
2016 1
2017 1
2018 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Hidalgo-Tenorio C, Pasquau J, Vinuesa D, Ferra S, Terrón A, SanJoaquín I, Payeras A, Martínez OJ, López-Ruz MÁ, Omar M, de la Torre-Lima J, López-Lirola A, Palomares J, Blanco JR, Montero M, García-Vallecillos C. Hidalgo-Tenorio C, et al. Among authors: terron a. Viruses. 2022 Mar 4;14(3):524. doi: 10.3390/v14030524. Viruses. 2022. PMID: 35336931 Free PMC article. Clinical Trial.
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas JR, Domingo P, Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. Saumoy M, et al. Among authors: terron a. AIDS Res Hum Retroviruses. 2017 Jan;33(1):29-32. doi: 10.1089/AID.2015.0386. Epub 2016 Dec 20. AIDS Res Hum Retroviruses. 2017. PMID: 27250802
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Pérez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Crespo M, Hernández-Quero J, Iribarren JA, Gutiérrez F, Terrón A, Esteban H, Pérez-Molina JA; GESIDA 7011 Study Group members. Pérez-Valero I, et al. Among authors: terron a. J Antimicrob Chemother. 2018 Sep 1;73(9):2444-2451. doi: 10.1093/jac/dky212. J Antimicrob Chemother. 2018. PMID: 29897573 Free article. Clinical Trial.
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C, Sequera S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Albendín-Iglesias H, Javier R, Ruz MÁL, Romero A, Garcia-Vallecillos C. Hidalgo-Tenorio C, et al. Among authors: terron a. Int J Antimicrob Agents. 2024 Jun;63(6):107164. doi: 10.1016/j.ijantimicag.2024.107164. Epub 2024 Apr 2. Int J Antimicrob Agents. 2024. PMID: 38574873 Free article. Clinical Trial.
Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
Pasquau J, López-Cortés L, Mayorga MI, Viciana P, Del Mar Arenas M, Ríos MJ, Hernández-Quero J, Castaño M, Merino MD, Márquez M, Vergara A, Terrón A, Téllez F, Hidalgo-Tenorio C. Pasquau J, et al. Among authors: terron a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19813. doi: 10.7448/IAS.17.4.19813. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397557 Free PMC article.
Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I. Estrada V, et al. Among authors: terron a. BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36. BMC Womens Health. 2011. PMID: 21816091 Free PMC article.
Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
Pere D, Ignacio SL, Ramón T, Fernando L, Alberto T, Pompeyo V, Juan G, M José G, Paloma G, Antonio V, Jaime C, Esteban R, Bernardino R, M Luisa GA, Trinitario S, Ferran T, Juan Ramón L, Myriam G. Pere D, et al. Among authors: alberto t. Open AIDS J. 2008;2:26-38. doi: 10.2174/1874613600802010026. Epub 2008 Mar 24. Open AIDS J. 2008. PMID: 18923695 Free PMC article.
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
Mira JA, Macías J, Girón-González JA, Merino D, González-Serrano M, Jiménez-Mejías ME, Caballero-Granado FJ, Torre-Cisneros J, Terrón A, Becker MI, Gómez-Mateos J, Arizcorreta-Yarza A, Pineda JA; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Mira JA, et al. Among authors: terron a. J Antimicrob Chemother. 2006 Jul;58(1):140-6. doi: 10.1093/jac/dkl214. Epub 2006 May 23. J Antimicrob Chemother. 2006. PMID: 16720565
Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort.
Teira R, Suárez-Lozano I, Lozano F, Viciana P, Domingo P, Galindo P, Geijo P, Terrón A, González J, Cosín J, Ribera E, Roca B, García-Alcalde ML, Sánchez T, Muñoz-Sánchez A, Vergara A, López-Aldeguer J, Pedrol E, Vidal F, Garrido M, Santamaría JM. Teira R, et al. Among authors: terron a. Enferm Infecc Microbiol Clin. 2010 May;28(5):266-72. doi: 10.1016/j.eimc.2009.04.018. Epub 2010 Feb 2. Enferm Infecc Microbiol Clin. 2010. PMID: 20129716
24 results